New Findings on Long-Term Efficacy of Lecanemab Presented at CTAD 2026 Conference
New Insights into Lecanemab's Extended Efficacy in Alzheimer's Treatment
On November 16, 2026, groundbreaking findings from the Clarity AD study regarding lecanemab, an innovative therapy for early Alzheimer's disease, were unveiled at the 19th Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston. These insights, shared by Eisai Co., Ltd. and Biogen Inc., emphasize the sustained benefits of long-term treatment with lecanemab, branded as LEQEMBI® in the U.S.
Understanding the Study Design
The Clarity AD study is a comprehensive Phase 3 trial that has been pivotal in assessing the efficacy of lecanemab. This randomized study involved 1,795 participants diagnosed with early Alzheimer's disease, who were split into lecanemab and placebo groups. Following the initial 18-month core study, a staggering 95% of patients elected to continue into a long-term extension study, showcasing their commitment to exploring the potential benefits of the treatment over a substantial period.
Results Highlight Sustained Cognitive Benefits
After a continuous five-year regimen of lecanemab, the results were stark. Patients exhibited a slower progression through the stages of Alzheimer's, with a notable reduction in decline as measured using the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB). Specifically, patients receiving lecanemab experienced a decrease in CDR-SB score changes, showing a -2.05 point difference at the five-year mark compared to natural disease progression data. Such findings underscore the therapy's ability to prolong early stage cognition and daily functioning positively.
Remarkable Findings on Low Tau Patients
A particularly promising aspect of the study was the focus on patients who presented low levels of tau accumulation in their brains. An impressive 66% showed no decline in cognitive function over five years, while 62% reported improvements in daily activities, reinforcing the notion that early intervention may yield long-lasting benefits.
Safety Profile: A Promising Overview
Notably, the safety profile of lecanemab remained consistent throughout the five years of treatment. Incidents of amyloid-related imaging abnormalities (ARIA-E) were primarily observed in the earliest treatment phases, demonstrating a decreasing frequency over time, particularly in comparison to placebo. This consistent safety profile supports the potential for lecanemab to be a viable long-term treatment solution for Alzheimer's patients.
Conclusion: A Paradigm Shift in Alzheimer's Treatment
The new data presented at CTAD 2026 not only bolster the position of lecanemab in the therapeutic landscape for early Alzheimer's disease but also advocate for the importance of early diagnosis and intervention. As Eisai and Biogen continue to collaborate on this important research, the emphasis on sustained benefits from continuous treatment could lead to transformative changes in patient care for those battling Alzheimer's disease.
For professionals and families touched by Alzheimer's, these findings offer a beacon of hope, underlining that early and persistent treatment with lecanemab may pave the way for improved cognitive outcomes and overall quality of life for patients.
For Further Information
Eisai and Biogen are committed to advancing Alzheimer's treatment through ongoing research and collaboration, aimed at fulfilling the unmet needs of patients and their families.